Please assess the completion status of the following clinical trial:

Trial Title: Danhong Injection in the Treatment of Unstable Angina Pectoris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male inpatients.~* Age: 35 - 75 years.~* Patients with clinical diagnosis of unstable stable angina according to China Guideline for the diagnosis and treatment of unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) (2007) issued by Chinese Society of Cardiology of Chinese Medical Association, including one of the following conditions.~* Clinical diagnosis of Xueyu Zheng (Blood Stasis Syndrome) as the scores of Chinese medicine symptoms scales of Xueyu Zheng in UA ≥ 15. The Chinese medicine symptoms scales of Xueyu Zheng is a 6-item questionnaire including the symtoms as following: (1)chest pain-10, (2)chest distress-10, (3) palpitation-5, (4)purple or dark lip-5, (5) purple or dark tongue-5, (6) unsmooth pulse-5.~* Patient is willing to participate voluntarily and to sign a written patient informed consent.~Exclusion Criteria:~* Patients with severe heart failure (EF\<35%);~* Patients with history of infection, fever, trauma, surgery(exclude PCI) and inflammation in the past month;~* Patients with active tuberculosis or rheumatological disorders;~* Patients with renal dysfunction (Male: CCr\>2.5mg/dl; Female: CCr\>2.0mg/dl);~* Patients with liver dysfunction (any value of serum aminotransferase more than triple normal value);~* Patients with history of hematopoietic system diseases;~* Patients with mental disorder;~* Patients with history of drug-induced bleeding or history of bleeding caused by warfarin;~* Patients with malignant tumor;~* Patients with history of organ transplant;~* Woman with pregnancy, lactation or positive result of pregnancy test;~* Patients who is participating in other trials or has been participated in other trials in recent 3 months;~* Patients who were unable to participate in the study as judged by investigator.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Danhong injection (Type: EXPERIMENTAL): Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2-3 hours every day for 7 days.
- Placebo (Type: PLACEBO_COMPARATOR): Based on the standard medical care, placebo was 40ml of 0.9% saline, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2-3 hours every day for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).